Your institution may have access to this item. Find your institution then sign in to continue.

Title: Real world evidence of changes in CGRP monoclonal antibody and onabotulinumtoxinA prescription practices at the start of the COVID‐19 pandemic: An observational, retrospective study.
Authors: Moskatel, Leon S.; Graber‐Naidich, Anna; He, Zihuai; Zhang, Niushen
Abstract: The article examines changes in prescription practices for CGRP monoclonal antibodies and onabotulinumtoxinA at the beginning of the COVID-19 pandemic, finding that providers initially switched to CGRP mAbs when onabotulinumtoxinA treatments were disrupted but later reverted to pre-pandemic patterns, indicating a preference for onabotulinumtoxinA when available for treating chronic migraine patients.
Subjects: THERAPEUTIC use of monoclonal antibodies; BOTULINUM toxin; SCIENTIFIC observation; NEUROPEPTIDES; CALCITONIN; RETROSPECTIVE studies; REGRESSION analysis; DRUG prescribing; DESCRIPTIVE statistics; PHYSICIAN practice patterns; HEADACHE; COVID-19 pandemic
Publication: Headache: The Journal of Head & Face Pain, 2023, Vol 63, Issue 8, p1180
ISSN: 0017-8748
Publication type: Academic Journal
DOI: 10.1111/head.14585

We found a match

Real world evidence of changes in CGRP monoclonal antibody and onabotulinumtoxinA prescription practices at the start of the COVID‐19 pandemic: An observational, retrospective study.